Autoimmune Hepatitis: 2026 Update

Autoimmune hepatitis (AIH) is an autoimmune liver disease characterized by immune-mediated hepatocellular destruction. This review provides a comprehensive update on the changes in the clinical landscape of and advancements in therapy for AIH up to 2026. Recent epidemiological data indicate a significant increase in both the incidence and prevalence of AIH worldwide, emphasizing potential shifts in environmental triggers and heightened disease awareness. Diagnosing AIH remains intricate owing to atypical manifestations; however, the newly updated 2025 European Association for the Study of the Liver clinical practice guidelines introduce refined simplified diagnostic criteria that incorporate contemporary laboratory platforms and international pathology standards to enhance real-world sensitivity. Immunosuppressive therapy continues to be the cornerstone of management. Corticosteroids remain the standard first-line treatment, while the upfront combination of prednisolone and mycophenolate mofetil is increasingly recommended alongside conventional azathioprine regimens. Achieving a complete biochemical response-defined as the normalization of transaminases and immunoglobulin G within 6 to 12 months-has emerged as a powerful, universally recognized surrogate endpoint for long-term prognosis, strongly predicting lower liver-related mortality and transplantation rates across both Western and Asian cohorts. Furthermore, this review addresses complex clinical entities, including drug-induced autoimmune-like hepatitis secondary to novel immunotherapies or vaccinations, and the phenotypic continuum of the primary biliary cholangitis-AIH overlap syndrome. Finally, we highlight the clinical utility of emerging, highly specific diagnostic biomarkers, such as anti-docking protein 2 antibodies-a promising candidate for seronegative cases, pending external multicenter validation-and outline essential directions for future AIH research.